Phase 3 trial of Covaxin to begin in Haryana on Nov 20, minister Anil Vij offers to be first volunteer

Haryana home minister Anil Vij on Wednesday announced that the third phase trial of Covaxin, Bharat Biotech International Limited’s potential vaccine candidate against the coronavirus disease (Covid-19), will begin on Friday in the state. Vij also offered to be the first volunteer for the vaccine trial.

“Trial for third phase of Covaxin a coronavirus vaccine product of Bhart Biotech to start in Haryana on 20th November. I have offered myself as first volunteer to get vaccinated,” the minister wrote on Twitter.

Bharat Biotech has begun the Phase 3 clinical trials of Covaxin with 26,000 participants across 22 sites in the country, the pharma firm had said on Monday. The Hyderabad-based drug maker is conducting the trial in collaboration with the Indian Council of Medical Research (ICMR).

“The Phase III trials will involve 26,000 volunteers across India, conducted in partnership with ICMR. It is the largest clinical trial conducted for a Covid-19 vaccine in India. This is India’s first phase 3 efficacy study for a Covid-19 vaccine, and the largest phase III efficacy trial ever conducted in India,” Bharat Biotech said in a statement.

The trial has been registered with the clinical trials registry of India and approved by the Drugs Controller General of India (DCGI).

Click here for complete coronavirus coverage

In Haryana, Pandit Bhagwat Dayal Sharma University of Health Sciences in Rohtak and ESIC hospital in Faridabad have been identified among those sites across the country where trials will be conducted, according to Bharat Biotech’s statement.

Trial volunteers, above the age of 18, will receive two intramuscular injections, about 28 days apart. “Participants will be randomly assigned to receive Covaxin or placebo. The trial is double-blinded, such that the investigators, the participants and the company will not be aware of who is assigned to which group,” the pharma firm said.

Covaxin has been evaluated in 1,000 subjects in phase I and phase II clinical trials, with promising safety and immunogenicity data, the statement added.

(With agency inputs)

Disclaimer: This post has not been edited by our staff and is published from a syndicated feed. The Original Source of this post can be found at Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest

‘Iran will give a calculated response to scientist killing’

Iran will give a “calculated and decisive” response to the killing of its top nuclear scientist, said a top...

F1 driver Grosjean escapes after horror crash at Bahrain GP

The 34-year-old French driver slid off track on the first lap and his Haas car burst into flames after being sliced in two by...

Navy finds some debris of crashed MiG-29K in Arabian sea

The Russian-origin jet had taken off from aircraft carrier INS Vikramaditya, and went down at around 5 p.m. on Thursday, officials had said, adding...

Fact-check: No, govt isn’t giving free laptops to students or jobs...

PM Narendra Modi reviewed the development of COVID-19 vaccine candidate ZyCOV-D in Ahmedabad. ...

Wasn’t any more nervous on my first day directing: Viggo Mortensen...

By: PTI | Los Angeles | November 29, 2020 8:14:17 pm Viggo Mortensen is making his feature directorial debut with the drama Falling. (Photo: AP)Actor...

More Articles